Disclaimer statement
Warning!
Science & technology
R&D pipeline
Taking life-changing innovations all the way
At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.
Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, rare blood and endocrine disorders, and other serious chronic diseases.
Explore our pipeline
Browse our entire R&D pipeline by study phase, or select a specific therapy areas. Click on a candidate to access up-to-date trial information.
Phase 1
Pumpsulin
Diabetes
Glucose sensitive insulin
Diabetes
Once weekly Oral Semaglutide
Diabetes
DNA immunotherapy
Diabetes
Amylin 355
Obesity
Oral Amycretin
Obesity
Subcutaneous Amycretin
Obesity
INV-347
Obesity
Amylin 1213
Obesity
Tri-agonist
Obesity
Anti ANGPTL3
Cardiovascular Disease
CNP
Cardiovascular Disease
NLRP3 inhibitor
Cardiovascular Disease
Cell Therapy in heart failure
Cardiovascular Disease
MARC1
Emerging Therapy Areas
LXRα
Emerging Therapy Areas
Cell therapy in Parkinson's disease
Emerging Therapy Areas
Inno8
Rare Blood Disorders
TMPRSS6
Rare Blood Disorders
Phase 2
CDR132L
Cardiovascular Disease
Subcutaneous Amycretin
Diabetes
NDec
Rare Blood Disorders
Coramitug
Cardiovascular Disease
FGF-21 MASH
Emerging Therapy Areas
Oral Amycretin
Diabetes
Etavopivat
Rare Blood Disorders
Monlunabant in DKD
Diabetes
Once weekly GLP-1/GIP
Diabetes
GELA
Obesity
Once weekly GLP-1/GIP
Obesity
Monlunabant
Obesity
GELA
Diabetes
Phase 3
Oral Semaglutide 25 mg and 50 mg
Diabetes
CagriSema in T2D
Diabetes
Oral Sema Obesity
Obesity
CagriSema
Obesity
Semaglutide 7.2 mg
Obesity
Mim8
Rare Blood Disorders
Ziltivekimab AMI
Cardiovascular Disease
Semaglutide MASH
Emerging Therapy Areas
Oral Semaglutide Alzheimer’s
Emerging Therapy Areas
Ziltivekimab ASCVD
Cardiovascular Disease
Ziltivekimabin HFpEF
Cardiovascular Disease
Etavopivat (Sickle Cell Disease)
Rare Blood Disorders
Filed
Icosema
Diabetes
Insulin icodec
Diabetes
Concizumab
Rare Blood Disorders
Explore more
Our scientific approach
Our Pharmaceutical Value Chain helps us to get innovative treatments and devices into the hands of patients who need them.
Finding the right target
Discovering better treatments takes research technologies that help unravel the biological complexity behind chronic diseases.